Return
Effect of Olezarsen on Lipoprotein-Associated ApoC-III Levels in Patients with Familial Chylomicronemia Syndrome
DOI:10.1016/j.atherosclerosis.2025.120462.png)
Abstract
En 中文
• In FCS, olezarsen lowers apoC-III across all major lipoprotein pools. • The largest reductions were in apoC-III on total apoB and apoA-I particles. • Modest effects were observed on apoC-III bound to apoB-100 and Lp(a) • Lipoprotein-specific assays reveal mechanistic treatment insights with olezarsen. • Measuring apoC-III across lipoproteins may guide future studies in pancreatitis and CVD.
Keywords:
olezarsen
apoC-III
lipoproteins
FCS
pancreatitis
CVD
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
5.7
Papers:
2.0W
Citations:
2.5W

